scispace - formally typeset
S

Salomon M. Stemmer

Researcher at Rabin Medical Center

Publications -  215
Citations -  12740

Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.

Papers
More filters
Journal ArticleDOI

Young patients and gastrointestinal (GI) tract malignancies - are we addressing the unmet needs?

TL;DR: The distinctive symptoms and areas of treatment-related functional impairments indicate there are unmet needs, especially in the area of psychosocial support and nutritional counseling, in young patients with GI cancers.
Journal ArticleDOI

The Influence of Mucositis on Oral Thermometry: When Fever May Not Reflect Infection

TL;DR: Mucositis causes an increase in oral temperature but does not elevate systemic body temperature, thereby casting doubt on the diagnosis of infection, and this concern should be tested and clarified in a prospective study based on accurate temperature measurement.
Journal ArticleDOI

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, +370 more
- 01 Oct 2021 - 
TL;DR: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumabs (CLEOPATRA) trial established the combination of pertuzumaab, trastuzumaba and docetaxel as standard first-line therapy for locally recurrent/metastatic breast cancer (LR/mBC).
Journal ArticleDOI

The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.

TL;DR: The addition of ZOL to letrozole was safe and efficacious in maintaining LS BMD in postmenopausal patients with hormone receptor-positive breast cancer and who were receiving letroZole following 2.5–3 years of tamoxifen.